Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2013. The report details a share repurchase transaction executed on June 6, 2013, pursuant to shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 905,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,681.0 pence per share; lowest price paid was 1,644.0 pence per share.
- Treasury Holdings (Settled): 505,534,512 shares (9.31% of total issued share capital).
- Treasury Holdings (Including Unsettled): 508,139,512 shares (10.32% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,923,717,913 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 905,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.32% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure under the Financial Conduct Authority's Disclosure and Transparency Rules regarding share ownership thresholds.
Investor Verification Checklist
- Verify the total number of shares in issue (4,923,717,913) for calculating disclosure thresholds under FCA rules.
- Confirm the current Treasury share count and its impact on total voting rights (10.32% including unsettled).
- Note that this announcement does not constitute an offer to purchase or subscribe for securities.